2013•Chinese journal of integrated traditional and Western medicineRequires access
A randomized,double-blind,controlled study of effect of oxymatrine sustained-release tablets in treatment for patients with HBeAg-positive chronic hepatitis B
Y Chen
Open publisher page 0 citations
Abstract
Objective: To investigate the clinical efficacy and safety of oxymatrine sustained-release tablets in treatment for patients with HBeAg-positive chronic hepatitis B. Methods: Forty patients with HBeAg-positive chronic hepatitis B were enrolled. The patients in control group and treatment group received oxymatrine capsules and sustained-release tablets,respectively,for 24 weeks,along with lamivudine therapy for 48 weeks. The levels of serum alanine aminotransferase( ALT) and HBV DNA were quantified at week 4,8,and 24. Results: Thirty-six patients accomplished the 24 weeks of treatment and observation. At week 24,serum HBV DNA were all decreased,and to the levels below the limit of detection in 38. 89% and 33. 33% of patients in treatment and control group,respectively. Sixty-six point sixty-seven percent and 72. 22% patients in treatment group and control group,respectively,got normal serum ALT. There were no significant differences in the rates of serum HBV DNA negative and ALT normalization between the two groups( P 0. 05). No sever adverse events occurred in neither group. Conclusion: Similar to oxymatrine capsules,oxymatrine sustained-release tablets are effective and safe in treatment for patients with HBeAg-positive chronic hepatitis B.